TY - JOUR
T1 - The 'regulatory' β-subunit of protein kinase CK2 negatively influences p53-mediated allosteric effects on Chk2 activation
AU - Bjørling-Poulsen, Marina
AU - Siehler, Simone
AU - Wiesmüller, Lisa
AU - Meek, David
AU - Niefind, Karsten
AU - Issinger, Olaf-Georg
PY - 2005/9/8
Y1 - 2005/9/8
N2 - The 'regulatory' beta-subunit of protein kinase CK2 has previously been shown to interact with protein kinases such as A-Raf, c-Mos, Lyn and Chk1 in addition to the catalytic subunit of CK2. Sequence alignments suggest that these interactions have a structural basis, and hence other protein kinases harboring corresponding sequences may be potential interaction partners for CK2beta. We show here that Chk2 specifically interacts with CK2beta in vitro and in cultured cells, and that activation of Chk2 leads to a reduction of this interaction. Additionally, we show that the presence of the CK2beta-subunit significantly reduces the Chk2-catalysed phosphorylation of p53 in vitro. These findings support the notion that CK2beta can act as a general modulator of remote docking sites in protein kinase--substrate interactions.
AB - The 'regulatory' beta-subunit of protein kinase CK2 has previously been shown to interact with protein kinases such as A-Raf, c-Mos, Lyn and Chk1 in addition to the catalytic subunit of CK2. Sequence alignments suggest that these interactions have a structural basis, and hence other protein kinases harboring corresponding sequences may be potential interaction partners for CK2beta. We show here that Chk2 specifically interacts with CK2beta in vitro and in cultured cells, and that activation of Chk2 leads to a reduction of this interaction. Additionally, we show that the presence of the CK2beta-subunit significantly reduces the Chk2-catalysed phosphorylation of p53 in vitro. These findings support the notion that CK2beta can act as a general modulator of remote docking sites in protein kinase--substrate interactions.
U2 - 10.1038/sj.onc.1208762
DO - 10.1038/sj.onc.1208762
M3 - Article
C2 - 15940255
SN - 0950-9232
VL - 24
SP - 6194
EP - 6200
JO - Oncogene
JF - Oncogene
IS - 40
ER -